UNSPSC 51172320: Deferasirox

This classification denotes a metal chelator with the molecular formula C21H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V8G4MOF2V9, chemically known as 4-(3,5-bis-(hydroxy-phenyl)-1,2,4)triazol-1-yl)-benzoic acid but generally known as deferasirox, which bears US NIH Compound Identifier 5493381. European Medicines Agency schedules Deferasirox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21981.

UNSPSC 51172320 Deferasirox is a Commodity code that nominally describes a specific iron-chelation pharmaceutical product, but recent state and local procurement activity under this code shows little relevance to deferasirox itself. Instead, the opportunities tagged to this code reflect broader pharmacy and pharmaceutical-services procurement across state health agencies, county criminal-justice departments, and cooperative purchasing alliances. The work actually being solicited includes offender drug-testing services with lab screening and confirmation, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical and OTC product distribution through established wholesaler channels. Issuing bodies span county departments of community supervision, state health and human services commissions, and multistate cooperative purchasing organizations. The mismatch between the code's specific drug name and the actual scope of recent opportunities suggests that deferasirox may be used as a catchall pharmaceutical-services code within some state and local procurement systems, or that tagging has diverged from the code's intended narrow scope.

Recent activity is concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services covering approximately 25,031 annual tests with an estimated contract value of $600,000 over two years with three optional one-year renewals; the county will award to one or more responsible contractors based on compliance, understanding, qualifications, references, and cost. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured employers and state agencies, with no award value identified at the information-gathering stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with product availability required by May 15, 2026, and contract effectiveness July 1, 2026; evaluation weights price competitiveness at 75 percent and administrative compliance at 20 percent combined.